SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its ...
For Maze’s MZE829 program, Guggenheim increased its probability of success estimate to 30% from 20% for diabetic AMKD (APOL1-mediated kidney disease), maintaining the same 30% probability for ...
The AmeriCares Free Clinic of Danbury is holding a Day at the Maze Saturday, from 10 a.m. until 10 p.m. to benefit the services provided by the free health clinic. The A-maiz-ing Maze is at Larsen's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback